<DOC>
	<DOC>NCT00242801</DOC>
	<brief_summary>This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous chemotherapy treatment.</brief_summary>
	<brief_title>Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Â· Life expectancy of at least 8 weeks. Histologically or cytologically confirmed nonsmall cell bronchogenic carcinoma: adenocarcinoma (including bronchoalveolar), squamous cell carcinoma, large cell carcinoma or mixed (adenocarcinoma and squamous) or undifferentiated carcinoma Not suitable for chemotherapy WHO Performance status 0,1, 2 or 3 Newly diagnosed CNS mets Less than 1 week since completion of prior radiotherapy or persistence of any radiotherapy related toxicity ALT/AST greater than 5 x upper limit of normal ANC less than 1.0 x 109/L or platelets less than 100 x 109/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>